Study identifier:D9673R00028
ClinicalTrials.gov identifier:NCT05573893
EudraCT identifier:N/A
CTIS identifier:N/A
Prospective non-interventional study (NIS) to examine patient-reported outcomes and real-world clinical data in patients with HER2-positive or HER2-low unresectable or metastatic breast cancer treated with Trastuzumab Deruxtecan
Breast Neoplasms
N/A
No
-
All
800
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Oct 2024 by AstraZeneca
AstraZeneca
Daiichi Sankyo
No locations available
Arms | Assigned Interventions |
---|---|
Cohort 1 Cohort 1 containing patients with documented HER2-positive unresectable or metastatic BC receiving T-DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice. | - |
Cohort 2 Cohort 2 containing patients with documented HER2-low unresectable or metastatic BC receiving T-DXd treatment in line with the applicable summary of product characteristics (SmPC) within routine clinical practice. | - |